Aldehyde-Binding Compound for Dry Eye Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dry eye disease is characterized by decreased tear film stability due to abnormal tear quality or quantity, leading to ocular surface inflammation and discomfort, triggered by toxic aldehydes produced in vivo that react with proteins and DNA, activating inflammatory molecules like NF-kappaB.
Innovation Solution
A small-molecule compound, represented by formula (I) or its pharmaceutically acceptable salts, forms complexes with aldehydes in vivo, reducing aldehyde toxicity and inflammation through eye drops or oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If toxic aldehydes are produced in vivo, then metabolic processes occur, but aldehyde toxicity increases and causes inflammation
Solution Approach 1:
The patent applies this principle by using the reactive nature of toxic aldehydes to bind with and neutralize them. The small-molecule compounds are designed to specifically react with aldehydes like MDA and 4HNE, converting these harmful substances into non-toxic adducts that can be safely eliminated, thereby transforming the harmful metabolic byproduct into a beneficial therapeutic mechanism
Solution Approach 2:
The small-molecule compounds act as intermediaries between the toxic aldehydes and the inflammatory response. These compounds bind to aldehydes first, preventing direct interaction between aldehydes and inflammatory pathways (such as NF-kappaB activation), thereby mediating and blocking the harmful effect transmission
2Quantity of substance
If aldehydes react with proteins and DNA, then chemically modified biomolecules are produced, but tissue injury occurs
Solution Approach 1:
The patent converts the harmful chemical modification of biomolecules by aldehydes into a beneficial process where the small-molecule compounds are modified instead. The compounds undergo controlled chemical modification by binding to aldehydes, forming stable adducts that prevent aldehyde-induced tissue damage while the modified compounds themselves remain non-harmful
3Ease of operation
If inflammatory molecules like NF-kappaB are activated, then immune response is triggered, but dry eye disease symptoms worsen
Solution Approach 1:
The patent applies preliminary action by preventing aldehyde activation of inflammatory molecules before the inflammatory cascade begins. The small-molecule compounds bind to aldehydes in advance, blocking their ability to activate NF-kappaB and other inflammatory pathways, thereby preventing the harmful immune response before it starts rather than treating it after activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces inflammation and improves tear film stability, treating dry eye disease and associated corneal inflammation.
Implementation Method 1
through complexation reaction with aldehydes in vivo, thereby reducing aldehyde toxicity
Data Source
AI summary
Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.